Dexmedetomidine vs. haloperidol in delirious, agitated, intubated patients: a randomised open-label trial
Open Access
- 19 May 2009
- journal article
- research article
- Published by Springer Science and Business Media LLC in Critical Care
- Vol. 13 (3), R75-10
- https://doi.org/10.1186/cc7890
Abstract
Agitated delirium is common in patients undergoing mechanical ventilation, and is often treated with haloperidol despite concerns about safety and efficacy. Use of conventional sedatives to control agitation can preclude extubation. Dexmedetomidine, a novel sedative and anxiolytic agent, may have particular utility in these patients. We sought to compare the efficacy of haloperidol and dexmedetomidine in facilitating extubation. We conducted a randomised, open-label, parallel-groups pilot trial in the medical and surgical intensive care unit of a university hospital. Twenty patients undergoing mechanical ventilation in whom extubation was not possible solely because of agitated delirium were randomised to receive an infusion of either haloperidol 0.5 to 2 mg/hour or dexmedetomidine 0.2 to 0.7 μg/kg/hr, with or without loading doses of 2.5 mg haloperidol or 1 μg/kg dexmedetomidine, according to clinician preference. Dexmedetomidine significantly shortened median time to extubation from 42.5 (IQR 23.2 to 117.8) to 19.9 (IQR 7.3 to 24) hours (P = 0.016). Dexmedetomidine significantly decreased ICU length of stay, from 6.5 (IQR 4 to 9) to 1.5 (IQR 1 to 3) days (P = 0.004) after study drug commencement. Of patients who required ongoing propofol sedation, the proportion of time propofol was required was halved in those who received dexmedetomidine (79.5% (95% CI 61.8 to 97.2%) vs. 41.2% (95% CI 0 to 88.1%) of the time intubated; P = 0.05). No patients were reintubated; three receiving haloperidol could not be successfully extubated and underwent tracheostomy. One patient prematurely discontinued haloperidol due to QTc interval prolongation. In this preliminary pilot study, we found dexmedetomidine a promising agent for the treatment of ICU-associated delirious agitation, and we suggest this warrants further testing in a definitive double-blind multi-centre trial. Clinicaltrials.gov NCT00505804Keywords
This publication has 38 references indexed in Scilit:
- Pharmacoepidemiology of QT‐interval prolonging drug administration in critically ill patientsPharmacoepidemiology and Drug Safety, 2008
- Effect of Sedation With Dexmedetomidine vs Lorazepam on Acute Brain Dysfunction in Mechanically Ventilated PatientsJAMA, 2007
- Delirium as a Predictor of Mortality in Mechanically Ventilated Patients in the Intensive Care UnitJAMA, 2004
- Torsade de pointes associated with the administration of intravenous haloperidol:a review of the literature and practical guidelines for useEnvironment, Development and Sustainability, 2003
- [Preliminary experience with dexmedetomidine treatment of confusional state and hyperadrenergic states at an intensive care unit].2002
- Clinical practice guidelines for the sustained use of sedatives and analgesics in the critically ill adultCritical Care Medicine, 2002
- DexmedetomidineDrugs, 2000
- Frequency, Severity, and Treatment of Agitation in Young versus Elderly Patients in the ICUPharmacotherapy: The Journal of Human Pharmacology and Drug Therapy, 2000
- Prospective evaluation of the Sedation-Agitation Scale for adult critically ill patientsCritical Care Medicine, 1999
- DECREASED EXTRAPYRAMIDAL SYMPTOMS WITH INTRAVENOUS HALOPERIDOL1987